News
Public · Published
Needham maintains Viridian Therapeutics at Buy, raises price target to $38 from $34
Needham kept its Buy rating on Viridian Therapeutics and raised its price target to $38 from $34. The new target is 11.8% higher than the previous target and implies 51.1% upside from the November 3 closing share price of $25.15.
Published:
Updated:
What happened
Needham kept its Buy rating on Viridian Therapeutics and raised its price target to $38 from $34. The new target is 11.8% higher than the previous target and implies 51.1% upside from the November 3 closing share price of $25.15.
Confirmed
Global impact / market context
A higher analyst target signals greater expected share value from Needham’s perspective, while the unchanged Buy rating indicates its recommendation did not change. If investors act on that view, buying could support demand for Viridian shares, but the target is an estimate, not a guaranteed price.
Analyst inference
The stated 51.1% upside is calculated against the November 3 close, so it reflects a comparison with that past share price rather than a forecast of near-term trading. The article gives no reason for the target increase or new company operating information.
Analyst inference
What to watch
- Watch for Viridian’s next reported operating or clinical updates; the article does not explain why Needham raised its target or identify a change in business expectations. Analyst inference
- Compare later analyst ratings and targets with Needham’s $38 target to see whether other analysts adopt similar expectations or take a different view. Analyst inference
- Track the share price against the November 3 close of $25.15 and Needham’s $38 target, while remembering neither past price nor target ensures future performance. Analyst inference
Evidence
- Original source link unavailable